Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-L1
Biotech
Combo may offer route back for Agenus' cervical cancer drug
Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for balstilimab, the biotech is back with fresh data.
James Waldron
Jan 23, 2023 10:47am
Could beta cells be the source of Type 1 diabetes after all?
Jul 5, 2022 8:25am
Checkpoint on track to add indications for cancer drug approval
Jun 16, 2022 3:49pm
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Aug 27, 2021 7:55am
Arcus, Gilead post scant analysis of clinical data on TIGIT drug
Jun 24, 2021 7:30am
BMS says LAG-3 drug scores with Opdivo
Mar 25, 2021 9:50am